HomeCompareNEPTF vs JNJ

NEPTF vs JNJ: Dividend Comparison 2026

NEPTF yields 2000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NEPTF wins by $4.879226400974806e+39M in total portfolio value
10 years
NEPTF
NEPTF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full NEPTF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NEPTF vs JNJ

📍 NEPTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNEPTFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NEPTF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NEPTF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEPTF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NEPTF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEPTF + JNJ for your $10,000?

NEPTF: 50%JNJ: 50%
100% JNJ50/50100% NEPTF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NEPTF
No analyst data
Altman Z
-36.6
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEPTF buys
0
JNJ buys
0
No recent congressional trades found for NEPTF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNEPTFJNJ
Forward yield2000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.879226400974806e+39M$30.3K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.879195005460081e+39M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NEPTF vs JNJ ($10,000, DRIP)

YearNEPTF PortfolioNEPTF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,592$272.30+$200.00MNEPTF
2$3,738,731,768,458$3,738,517,757,009.35$11,289$357.73+$3738731.76MNEPTF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,123$472.89+$65315062866.92MNEPTF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,141$629.86+$1066400830062625.00MNEPTF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$14,408$846.81+$16272182796453826560.00MNEPTF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$16,021$1,151.60+$2.3205424011366188e+23MNEPTF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$18,122$1,588.22+$3.0927990661046884e+27MNEPTF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$20,930$2,228.20+$3.8524105697352695e+31MNEPTF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$4.484688260147987e+35MNEPTF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.879226400974806e+39MNEPTF

NEPTF vs JNJ: Complete Analysis 2026

NEPTFStock

Neptune Wellness Solutions Inc. operates as a consumer packaged goods company in Canada, the United States, and internationally. It's product portfolio includes omega-3 fish oils and other nutritional products, as well as softgel solutions under the Biodroga brand; and provides MaxSimil, an omega-3 fatty acid delivery technology that uses enzymes to predigest omega-3 fatty acids. The company offers vegan multi-omega gummies and soft gels under the Forest Remedies brand; and organic baby food products under the Sprout brands. It offers its products through distributors, retail outlets, and grocery stores, as well as online on forestremedies.com and sproutorganics.com, and e-commerce sites. Neptune Wellness Solutions Inc. was incorporated in 1998 and is headquartered in Laval, Canada.

Full NEPTF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NEPTF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEPTF vs SCHDNEPTF vs JEPINEPTF vs ONEPTF vs KONEPTF vs MAINNEPTF vs ABBVNEPTF vs MRKNEPTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.